Published in Proc Natl Acad Sci U S A on August 28, 2001
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A (2007) 13.58
The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16
A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep (2008) 10.71
Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol (2014) 10.04
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol (2009) 8.63
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73
Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest (2009) 6.70
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A (2011) 5.53
Cancer stem cells: mirage or reality? Nat Med (2009) 5.20
The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene (2007) 4.90
EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest (2009) 4.41
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res (2009) 4.24
The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer? EMBO Rep (2010) 4.05
Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia (2010) 3.93
Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev (2013) 3.63
To differentiate or not--routes towards metastasis. Nat Rev Cancer (2012) 3.59
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res (2011) 3.25
The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest (2002) 3.23
Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPK. J Cell Biol (2003) 3.09
Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med (2009) 3.05
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
Phosphorylation regulates the subcellular location and activity of the snail transcriptional repressor. Mol Cell Biol (2003) 2.46
β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci U S A (2011) 2.45
Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal (2014) 2.42
Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene (2011) 2.42
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut (2012) 2.40
L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol (2005) 2.39
Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer (2010) 2.31
Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis (2008) 2.30
The potential role of podoplanin in tumour invasion. Br J Cancer (2006) 2.20
Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell (2013) 2.08
IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res (2011) 2.08
β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med (2012) 2.02
The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep (2002) 1.93
Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget (2010) 1.88
Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One (2011) 1.87
Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir (2009) 1.79
Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells (2008) 1.78
MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis. J Clin Invest (2013) 1.76
Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer (2007) 1.75
Nuclear export of the APC tumour suppressor controls beta-catenin function in transcription. EMBO J (2003) 1.75
Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition. Cancer Res (2010) 1.74
Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J (2009) 1.67
Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res (2011) 1.67
The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis (2008) 1.65
Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. Oncogene (2009) 1.64
Drugging Wnt signalling in cancer. EMBO J (2012) 1.63
Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. J Cell Sci (2013) 1.63
E-cadherin engagement stimulates proliferation via Rac1. J Cell Biol (2006) 1.61
Modeling the influence of the E-cadherin-beta-catenin pathway in cancer cell invasion: a multiscale approach. Biophys J (2008) 1.57
Characterisation of integrin-linked kinase signalling in sporadic human colon cancer. Br J Cancer (2003) 1.57
Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. J Cell Biol (2010) 1.55
Tissue geometry patterns epithelial-mesenchymal transition via intercellular mechanotransduction. J Cell Biochem (2010) 1.53
The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol (2017) 1.52
Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway. Mol Biol Cell (2005) 1.51
The miR200 family of microRNAs regulates WAVE3-dependent cancer cell invasion. J Biol Chem (2009) 1.49
Selection and adaptation during metastatic cancer progression. Nature (2013) 1.46
Epithelial-Mesenchymal Transition in tumor microenvironment. Cell Biosci (2011) 1.40
Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer (2012) 1.39
Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets (2011) 1.38
Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron (2011) 1.37
Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer (2002) 1.37
Stem cells and cancer of the stomach and intestine. Mol Oncol (2010) 1.37
Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad Sci U S A (2006) 1.36
Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer. Cell Cycle (2011) 1.34
Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/β-catenin signal pathway. PLoS One (2013) 1.34
Molecular identification and targeting of colorectal cancer stem cells. Oncotarget (2010) 1.33
Expression and nuclear localization of Snail, an E-cadherin repressor, in adenocarcinomas of the upper gastrointestinal tract. Virchows Arch (2005) 1.33
Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer. PLoS One (2013) 1.32
Wnt/β-catenin activation promotes prostate tumor progression in a mouse model. Oncogene (2010) 1.30
Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer. Oncotarget (2013) 1.27
Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am J Cancer Res (2011) 1.26
Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. Br J Cancer (2008) 1.26
Complex patterns of altered MicroRNA expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer. Clin Cancer Res (2011) 1.25
Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia (2013) 1.25
Involvement of Src family kinases in N-cadherin phosphorylation and beta-catenin dissociation during transendothelial migration of melanoma cells. Mol Biol Cell (2005) 1.24
TGF-β-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Rep (2013) 1.24
Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res (2012) 1.23
Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness. Mol Biol Cell (2004) 1.22
EMT and MET in carcinoma--clinical observations, regulatory pathways and new models. Clin Exp Metastasis (2008) 1.21
LEF-1 and TCF4 expression correlate inversely with survival in colorectal cancer. J Transl Med (2010) 1.20
Constitutive IKK2 activation in intestinal epithelial cells induces intestinal tumors in mice. J Clin Invest (2011) 1.20
Dose-dependent roles for canonical Wnt signalling in de novo crypt formation and cell cycle properties of the colonic epithelium. Development (2013) 1.19
From single cells to tissue architecture-a bottom-up approach to modelling the spatio-temporal organisation of complex multi-cellular systems. J Math Biol (2008) 1.18
Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. Am J Cancer Res (2011) 1.18
Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol (2009) 1.17
PTEN loss induces epithelial--mesenchymal transition in human colon cancer cells. Anticancer Res (2009) 1.17
Pancreatic cancer stem cells: emerging target for designing novel therapy. Cancer Lett (2012) 1.16
Snail1 protein in the stroma as a new putative prognosis marker for colon tumours. PLoS One (2009) 1.16
Deletion of the proline-rich region of the murine metastasis susceptibility gene Brd4 promotes epithelial-to-mesenchymal transition- and stem cell-like conversion. Cancer Res (2011) 1.16
Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci (2010) 1.15
Tumour-stroma interactions in colorectal cancer: converging on beta-catenin activation and cancer stemness. Br J Cancer (2008) 1.13
Type I collagen inhibits differentiation and promotes a stem cell-like phenotype in human colorectal carcinoma cells. Br J Cancer (2009) 1.13
Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas. Am J Surg Pathol (2010) 1.13
The NF-κB/AKT-dependent Induction of Wnt Signaling in Colon Cancer Cells by Macrophages and IL-1β. Cancer Microenviron (2009) 1.13
Intestinal adenomagenesis involves core molecular signatures of the epithelial-mesenchymal transition. J Mol Histol (2008) 1.12
Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis. Front Biosci (Landmark Ed) (2011) 1.12
Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res (2014) 1.09
The hallmarks of cancer. Cell (2000) 113.05
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (1997) 22.80
Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature (1999) 20.34
A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature (1998) 8.48
E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res (1994) 4.51
Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol (1998) 4.43
Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A (1999) 4.35
Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol (1999) 4.04
The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene (1999) 3.95
General mechanisms of metastasis. Cancer (1997) 3.71
Cadherins, catenins and APC protein: interplay between cytoskeletal complexes and signaling pathways. Curr Opin Cell Biol (1997) 3.52
beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol (1999) 3.47
Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res (1991) 3.47
APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits". Proc Natl Acad Sci U S A (2000) 3.41
Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover. Nat Cell Biol (2000) 3.14
Beta-catenin as oncogene: the smoking gun. Science (1997) 3.13
Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem (2000) 2.97
Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res (1999) 2.84
The APC tumour suppressor has a nuclear export function. Nature (2000) 2.82
The Wnt/Wg signal transducer beta-catenin controls fibronectin expression. Mol Cell Biol (1999) 2.68
Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract (1998) 2.63
Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC-/- human colon carcinoma cells. Oncogene (2001) 2.16
Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc Natl Acad Sci U S A (1998) 1.70
Expression of nuclear beta-catenin and c-myc is correlated with tumor size but not with proliferative activity of colorectal adenomas. Am J Pathol (2000) 1.66
The PDZ domains of zonula occludens-1 induce an epithelial to mesenchymal transition of Madin-Darby canine kidney I cells. Evidence for a role of beta-catenin/Tcf/Lef signaling. J Biol Chem (2000) 1.65
Down-regulation of beta-catenin TCF signaling is linked to colonic epithelial cell differentiation. Cancer Res (2001) 1.64
Multicellular tumor spheroids: intermediates between monolayer culture and in vivo tumor. Cell Biol Int (1999) 1.63
Patterning and nuclear beta-catenin expression in the colonic adenoma-carcinoma sequence. Analogies with embryonic gastrulation. Am J Pathol (2000) 1.56
CRM1- and Ran-independent nuclear export of beta-catenin. Curr Biol (2001) 1.47
Human colorectal cancers with an intact p16/cyclin D1/pRb pathway have up-regulated p16 expression and decreased proliferation in small invasive tumor clusters. Am J Pathol (2000) 1.33
Predictive value of nuclear beta-catenin expression for the occurrence of distant metastases in rectal cancer. Dis Colon Rectum (1998) 1.20
Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of beta-catenin/T-cell factor 4-mediated gene transactivation. Cancer Res (2001) 1.15
The Vienna classification of gastrointestinal epithelial neoplasia. Gut (2000) 9.39
Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology (1992) 4.19
Exons encode functional and structural units of chicken lysozyme. Proc Natl Acad Sci U S A (1980) 4.01
Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology (1998) 3.82
Human Y chromosome azoospermia factors (AZF) mapped to different subregions in Yq11. Hum Mol Genet (1996) 3.78
beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol (1999) 3.47
Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest (1996) 2.96
Central nervous system lesions and cervical disc herniations in amateur divers. Lancet (1995) 2.84
Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J Mol Endocrinol (2006) 2.81
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch (2008) 2.78
Imported lassa fever in Germany: molecular characterization of a new lassa virus strain. Emerg Infect Dis (2000) 2.69
Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract (1998) 2.63
Multiple mRNAs are generated from the chicken lysozyme gene. Cell (1981) 2.46
Expression of CD68 in non-myeloid cell types. Scand J Immunol (2008) 2.32
CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer (2008) 2.23
Tumor-associated fibroblasts (part I): Active stromal participants in tumor development and progression? Histol Histopathol (2002) 1.84
Expression of the invasion factor laminin gamma2 in colorectal carcinomas is regulated by beta-catenin. Cancer Res (2001) 1.83
The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res (1973) 1.77
The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. Am J Pathol (2001) 1.73
Multicellular spheroids: a three-dimensional in vitro culture system to study tumour biology. Int J Exp Pathol (1998) 1.70
Antrum- and corpus mucosa-infiltrating CD4(+) lymphocytes in Helicobacter pylori gastritis display a Th1 phenotype. Infect Immun (1998) 1.67
Expression of nuclear beta-catenin and c-myc is correlated with tumor size but not with proliferative activity of colorectal adenomas. Am J Pathol (2000) 1.66
Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridisation. Gut (2000) 1.62
Characterization of a protein with an acetylcholine receptor epitope from myasthenia gravis-associated thymomas. Lab Invest (1990) 1.60
Growth and symptoms in Silver-Russell syndrome: review on the basis of 386 patients. Eur J Pediatr (1995) 1.59
Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology (1994) 1.55
Development of a standard set of microsatellite reference alleles for identification of grape cultivars. Theor Appl Genet (2004) 1.52
Overexpression of Dicer predicts poor survival in colorectal cancer. Eur J Cancer (2011) 1.46
Lack of evidence for an involvement of Epstein-Barr virus infection of synovial membranes in the pathogenesis of rheumatoid arthritis. Arthritis Rheum (2000) 1.40
Innate immunity in cystic fibrosis lung disease. J Cyst Fibros (2012) 1.38
Tumor cells in blood shed from the surgical field. Arch Surg (1995) 1.28
Isolation and characterization of a 14.5-kDa trichloroacetic-acid-soluble translational inhibitor protein from human monocytes that is upregulated upon cellular differentiation. Eur J Biochem (1996) 1.28
Heterogeneity among Whipple's-disease-associated bacteria. Lancet (1994) 1.28
Mitochondrial oxidative phosphorylation is a downstream regulator of nitric oxide effects on chondrocyte matrix synthesis and mineralization. Arthritis Rheum (2000) 1.27
Mechanisms of sulfadoxine resistance in Plasmodium falciparum. Mol Biochem Parasitol (1986) 1.27
The gastric H+,K+-ATPase is a major autoantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy. Gastroenterology (1998) 1.26
Can an endocytoscope system (ECS) predict histology in neoplastic lesions? Endoscopy (2007) 1.25
Negative regulation of CD4 expression in T cells by the transcriptional repressor ZEB. Int Immunol (1999) 1.24
Tumor-associated fibroblasts (part II): Functional impact on tumor tissue. Histol Histopathol (2002) 1.22
Expression of Cx26, Cx32 and Cx43 gap junction proteins in normal and neoplastic human tissues. Int J Cancer (1992) 1.22
Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J Clin Invest (1988) 1.21
Stage-dependent inhibition of chloroquine on Plasmodium falciparum in vitro. J Parasitol (1986) 1.21
Evaluation of membrane physiology following fluorescence activated or magnetic cell separation. Cytometry (1999) 1.21
Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene (2001) 1.21
Predictive value of nuclear beta-catenin expression for the occurrence of distant metastases in rectal cancer. Dis Colon Rectum (1998) 1.20
Late pulmonary metastasis in uterine PEComa. J Clin Pathol (2003) 1.20
A heterologous 3-D coculture model of breast tumor cells and fibroblasts to study tumor-associated fibroblast differentiation. Exp Cell Res (2001) 1.17
The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation. Oncogene (2007) 1.17
Epidemiology of Whipple's disease in Germany. Analysis of 110 patients diagnosed in 1965-95. Scand J Gastroenterol (1997) 1.16
Chondroblastoma is an osteoid-forming, but not cartilage-forming neoplasm. J Pathol (1999) 1.14
Antigastric autoantibodies in Helicobacter pylori infection: implications of histological and clinical parameters of gastritis. Gut (1997) 1.13
Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab Invest (2000) 1.12
Ossifying lipoma. Virchows Arch (1999) 1.12
Antigastric autoantibodies in Helicobacter pylori gastritis: prevalence, in-situ binding sites and clues for clinical relevance. Virchows Arch (1996) 1.10
Helicobacter pylori induces apoptosis in gastric mucosa through an upregulation of Bax expression in humans. Scand J Gastroenterol (1999) 1.10
Characterization of lymphocytic infiltrates in Helicobacter pylori-associated gastritis. Scand J Gastroenterol (1996) 1.09
Multiple NF-ATc isoforms with individual transcriptional properties are synthesized in T lymphocytes. J Immunol (1999) 1.08
Fate of intravenously injected pyrophosphate-32P in dogs. Am J Physiol (1970) 1.07
Immunohistological evidences of cortical and medullary differentiation in thymoma. Virchows Arch A Pathol Anat Histopathol (1985) 1.07
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer (2012) 1.07
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol (2014) 1.07
ANT1, an aromatic and neutral amino acid transporter in Arabidopsis. Plant Physiol (2001) 1.06
Plasmodium vinckei: suppression of mouse infections with desferrioxamine B. Exp Parasitol (1985) 1.05
Efficacy of surgical measures in preventing port-site recurrences in a porcine model. Surg Endosc (2001) 1.04
Bugs on trial: the case of Helicobacter pylori and autoimmunity. Immunol Today (1998) 1.04
Inorganic pyrophosphate pool size and turnover rate in arthritic joints. J Clin Invest (1975) 1.03
Epstein-Barr virus small RNA (EBER) genes: differential regulation during lytic viral replication. J Virol (1998) 1.03
Monoclonal Epstein-Barr virus genomes but lack of EBV-related protein expression in different types of gastric carcinoma. Histopathology (1994) 1.03
Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer. Radiother Oncol (1998) 1.02
Labeling fibroblasts with biotin-BSA-GdDTPA-FAM for tracking of tumor-associated stroma by fluorescence and MR imaging. Magn Reson Med (2005) 1.01
Pseudoappendicitis caused by Plesiomonas shigelloides. J Clin Microbiol (1988) 1.01
Metabolic imaging in multicellular spheroids of oncogene-transfected fibroblasts. J Histochem Cytochem (2000) 1.00
Cell differentiation and matrix gene expression in mesenchymal chondrosarcomas. Am J Pathol (2000) 1.00
Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol (1999) 1.00
Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone (1988) 1.00
Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol (2003) 1.00
The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. Int J Cancer (2011) 0.99
Epithelial-mesenchymal and mesenchymal-epithelial transitions during cancer progression. Verh Dtsch Ges Pathol (2007) 0.99